Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes.

Next Previous
Trial Profile

Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Metformin
  • Indications Coronary artery disease; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms AddHope2

Most Recent Events

  • 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
  • 19 Oct 2016 Results assessing the effect of liraglutide on heart rate and heart rate variability over 12 weeks published in the Diabetes Care.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top